Q3 Earnings Forecast for MLTX Issued By Wedbush

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Stock analysts at Wedbush issued their Q3 2024 earnings per share estimates for MoonLake Immunotherapeutics in a research note issued to investors on Monday, November 4th. Wedbush analyst Y. Zhong expects that the company will post earnings per share of ($0.35) for the quarter. Wedbush currently has a “Strong-Buy” rating on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.54) per share. Wedbush also issued estimates for MoonLake Immunotherapeutics’ Q4 2024 earnings at ($0.38) EPS, FY2024 earnings at ($1.33) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.82) EPS, FY2027 earnings at ($1.59) EPS and FY2028 earnings at $0.38 EPS.

MLTX has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, October 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $62.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday, September 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of MoonLake Immunotherapeutics in a research report on Monday, September 23rd. Finally, Wolfe Research lowered MoonLake Immunotherapeutics from an “outperform” rating to a “peer perform” rating in a research report on Monday, August 26th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $78.73.

MoonLake Immunotherapeutics Trading Down 1.6 %

Shares of MLTX opened at $50.67 on Thursday. The firm has a market capitalization of $3.24 billion, a P/E ratio of -55.68 and a beta of 1.28. The stock’s fifty day simple moving average is $49.25 and its 200 day simple moving average is $45.32. MoonLake Immunotherapeutics has a twelve month low of $35.53 and a twelve month high of $64.98.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.11). During the same period last year, the firm earned ($0.23) earnings per share.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. grew its stake in MoonLake Immunotherapeutics by 24.7% in the third quarter. Victory Capital Management Inc. now owns 217,839 shares of the company’s stock worth $10,983,000 after purchasing an additional 43,157 shares in the last quarter. GSA Capital Partners LLP boosted its stake in MoonLake Immunotherapeutics by 1.9% in the third quarter. GSA Capital Partners LLP now owns 22,127 shares of the company’s stock valued at $1,116,000 after acquiring an additional 403 shares during the period. AlphaCentric Advisors LLC acquired a new position in MoonLake Immunotherapeutics in the third quarter valued at approximately $706,000. Harbor Capital Advisors Inc. raised its holdings in shares of MoonLake Immunotherapeutics by 100.2% during the third quarter. Harbor Capital Advisors Inc. now owns 77,468 shares of the company’s stock valued at $3,906,000 after buying an additional 38,779 shares during the last quarter. Finally, Rice Hall James & Associates LLC bought a new stake in shares of MoonLake Immunotherapeutics during the third quarter valued at approximately $3,805,000. 93.85% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at MoonLake Immunotherapeutics

In other news, Director Simon Sturge sold 171,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Friday, October 4th. The stock was sold at an average price of $53.72, for a total transaction of $9,186,120.00. Following the sale, the director now directly owns 171,980 shares of the company’s stock, valued at approximately $9,238,765.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 12.02% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.